{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T09:53:30Z","timestamp":1694339610127},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.clinthera.2008.10.010","type":"journal-article","created":{"date-parts":[[2008,11,18]],"date-time":"2008-11-18T06:26:59Z","timestamp":1226989619000},"page":"1831-1843","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: A single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers"],"prefix":"10.1016","volume":"30","author":[{"given":"Bashar A.","family":"Alkhalidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaafar J.","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isam I.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husain","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alsayed Alarabi I.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.10.010_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7164\/antibiotics.37.187","article-title":"Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A","volume":"37","author":"Morimoto","year":"1984","journal-title":"J Antibiot (Tokyo)"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2008.10.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/27.suppl_A.1","article-title":"The development of macrolides: Clarithromycin in perspective","volume":"27","author":"Neu","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2008.10.010_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/27.suppl_A.11","article-title":"In-vitro activity of clarithromycin combined with its 14-hydoxy metabolite A-62671 against Haemophilus influenzae","volume":"27","author":"Olsson-Liljequist","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2008.10.010_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/AAC.36.5.1147","article-title":"Absolute bioavailability of clarithromycin after oral administration in humans","volume":"36","author":"Chu","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2008.10.010_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0195-6701(91)90215-T","article-title":"The pharmacokinetics of clarithromycin and its 14-OH metabolite","volume":"19","author":"Davey","year":"1991","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.clinthera.2008.10.010_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-199325030-00003","article-title":"Clarithromycin clinical pharmacokinetics","volume":"25","author":"Fraschini","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2008.10.010_bib7","first-page":"213","article-title":"Metabolic fate of TE-031 A-56268 III. Absorption, distribution and excretion of 14C-TE-031 in rats, mice and dogs","volume":"36","author":"Suwa","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2008.10.010_bib8","series-title":"Biaxin XL [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2008.10.010_bib9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0149-2918(01)80060-6","article-title":"Pharmacokinetics and tolerability of extended-release clarithromycin","volume":"23","author":"Guay","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.10.010_bib10","first-page":"171","article-title":"Bioequivalence of two formulations of modified-release clarithromycin available in the Chilean market [in Spanish]","volume":"20","author":"Gaete","year":"2003","journal-title":"Rev Chil Infectol"},{"key":"10.1016\/j.clinthera.2008.10.010_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/03639049809085597","article-title":"Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties","volume":"24","author":"Ishii","year":"1998","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.clinthera.2008.10.010_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/j.1552-4604.1992.tb03784.x","article-title":"Drugfood interaction potential of clarithromycin, a new macrolide antimicrobial","volume":"32","author":"Chu","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2008.10.010_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1128\/AAC.42.4.927","article-title":"Effect of grapefruit juice on clarithromycin pharmacokinetics","volume":"42","author":"Cheng","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2008.10.010_bib14","series-title":"Ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000","author":"World Medical Association Declaration of Helsinki","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib15","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1)","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib16","series-title":"The United States Pharmacopeia and National Formulary-Usp 26 Nf 21","year":"2003"},{"key":"10.1016\/j.clinthera.2008.10.010_bib17","series-title":"Guidance for industry. Dissolution testing of immediate release solid dosage forms. August 1997","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0021-9673(94)00610-L","article-title":"Liquid chromatographic determination of the macrolide antibiotics roxithromycin and clarithromycin in plasma by automated solid-phase extraction and electrochemical detection","volume":"692","author":"Hedenmo","year":"1995","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.clinthera.2008.10.010_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0378-4347(99)00512-5","article-title":"Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high performance liquid chromatography with amperometric detection","volume":"738","author":"Taninaka","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.clinthera.2008.10.010_bib20","series-title":"Guidance for industry. Bioanalytical method validation. May 2001","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib21","series-title":"Good Laboratory Practice Regulations","author":"Hirsch","year":"1989"},{"key":"10.1016\/j.clinthera.2008.10.010_bib22","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.clinthera.2008.10.010_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2008.10.010_bib24","series-title":"Handbook of Basic Pharmacokinetics...including Clinical Applications","author":"Ritschel","year":"1992"},{"key":"10.1016\/j.clinthera.2008.10.010_bib25","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995"},{"key":"10.1016\/j.clinthera.2008.10.010_bib26","series-title":"Pharmaceutical Statistics: Practical and Clinical Applications","author":"Bolton","year":"1997"},{"key":"10.1016\/j.clinthera.2008.10.010_bib27","series-title":"Guidance for industry. Statistical approaches to establishing bioequivalence. January 2001","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib28","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","year":"2000"},{"key":"10.1016\/j.clinthera.2008.10.010_bib29","series-title":"Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Revision 1. March 2003","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib30","series-title":"Guidance for industry. Food-effect bioavailability and fed bioequivalence studies: Study design, data analysis, and labeling. December 2002","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib31","series-title":"Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.clinthera.2008.10.010_bib32","series-title":"Draft guidance on clarithromycin","author":"Center for Drug Evaluation and Research, US Food and Drug Administration","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T10:23:58Z","timestamp":1557915838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808003317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0149291808003317"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.10.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}